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Background:Cardiomyopathies is a group of heart diseases that directly affects the heart muscle, and their causes is not just high
blood pressure, congenital and pericardial diseases but ischemic cardiomyopathy disease are also caused by vascular disorders,
and to conﬁrm the diagnosis, angiography is required. There are several methods for treating and controlling ischemic
cardiomyopathy in world health systems and especially in the Iran health system, which include medical treatment, percutaneous
coronary intervention (PCI), and coronary artery bypass graft (CABG).
Methods: This systematic review will includes observational and interventional studies in English and Persian languages and
evaluates effectiveness of revascularization interventions and medical therapy in patients with ischemic cardiomyopathy. Animal
studies will not be considered. In this systematic review, our sources of information will be electronic databases, trial registries, and
different types of grey literature. An electronic search is performed through PubMed, Cochrane library, Scopus, Web of Science,
EMBASE, Tufts Medical Center Cost-Effectiveness Analysis Registry, NHS Economic Evaluations Database. To integrate the results
of studies with similar results, meta-analysis will be used, for which Comprehensive Meta-Analysis (CMA) software will be used.
Results are provided using relative risk with a 95% conﬁdence interval for information.
Results: The results of this systematic review will be published in a peer-reviewed journal.
Conclusion: To our knowledge, this systematic review will be the ﬁrst to evaluate existing research on the effectiveness of
revascularization interventions compared with medical therapy in patients with ischemic cardiomyopathy. The review will beneﬁt
patients, healthcare providers, and policymakers.
Abbreviations: CABG = coronary artery bypass graft, CABS = coronary artery bypass surgery, CMA = Comprehensive Meta-
Analysis, PCI = percutaneous coronary intervention.
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1Key Points
 This systematic review will develops a consensus on the
effectiveness of revascularization interventions compared
with medical therapy in medical articles.
 In this systematic review, databases in languages other
than English and Persian (French, German, Chinese, etc)
will not be searched or included. This limitation may
cause language bias.1. Introduction
Heart ischemic diseases, a group of heart failure, are categorized
into 2 acute and chronic groups, and its chronic category is
cardiovascular atherosclerotic, aneurysm, ischemic cardiomyop-
athy, and myocardial ischemia. Cardiac ischemic disease is a
condition that reduces blood ﬂow to the heart muscle, which can
disrupt the ﬂow of blood through coronary arteries, most often it
happens because of atherosclerotic stenosis, but sometimes also
because of arterial spasm.[1,2] Cardiomyopathy is also a group of
heart diseases that directly affects the heart muscle and is not only
due to high blood pressure, congenital, pericardial disease, but
Rezapour et al. Medicine (2018) 97:10 Medicinealso cardiomyopathy ischemia is due to vascular disorders, and to
conﬁrm this diagnosis, angiography is required.[3]
There are several methods for treating and controlling ischemic
cardiomyopathy in world health systems and especially in the
Iran health system, which include:- Medical therapy, such as the use of anticoagulants such as
thrombolytic, beta blocker, calcium blocker, antiarrhythmic,
nitrates, diuretics, antiplatelet, and lipid regulating drugs.[4,5]
Percutaneous Coronary Intervention, including piercing the-
skin to access the femoral artery by catheter, guide catheter-
guided balloon to narrow or blocked coronary artery, inﬂating
the balloon and dilating coronary stenting to prevent
reblockage.[2,6]
Coronary Artery Bypass Surgery includes the creation of bypass-
with saphenous vein or arterial graft pieces of breast through
open narrowed or blocked coronary sternum in place.[6] This is
a surgical technique that involves opening the chest and the
tight and closed coronary artery and is usually done by using the
vein or artery from other parts of the body. The advantages of
this surgical technique include angina relief in 60% to 90%
patients in the ﬁrst year, a signiﬁcant reduction in the mortality
of the disease when combined with drug therapy, and a
reduction in revascularization after 1 year, and its disadvan-
tages are high costs, in particular hospital care costs, and an
increase in myocardial infarction rate compared with drug
therapy.[7,8]
It is necessary to explain that coronary artery bypass graft
(CABG) and percutaneous coronary intervention (PCI) are part
of the ischemic myocardial revascularization techniques that are
used to relieve coronary artery obstruction and therefore their use
in patients with ischemic cardiomyopathy relieves pain and heals
the patient.[9]
So far, no systematic reviews have been made on this topic, But
here are the results of some relevant studies. Medical treatment
for coronary disease has advanced dramatically in recent years
and produced prognostic beneﬁts in the context of properly
designed, randomized, controlled trials. Surgical techniques have
also advanced but it is difﬁcult to be sure that they have really
reduced mortality because such comparisons are retrospective
rather than concurrent. Even if the proportionate beneﬁts from
surgery were to increase, the falling mortality with optimal
medical therapy will reduce the absolute beneﬁts of surgery over
medical treatment. Thus, the surgical interventions are being
superseded and their relevance to modern medical practice must
be questioned,[5,10] and in a clinical trial study in the ﬁeld of drug
therapy compared with surgery in patients with ischemic heart
disease, there was no signiﬁcant evidence of the beneﬁt of these 2
therapies in reducing mortality and morbidity[11]; in another
study, the effect of surgical intervention was similar to that of
drug therapy in patients with heart disease,[12] and in a meta-
analysis study, surgical intervention, compared with drug
therapy, led to greater reduction in the mortality rate of patients
with heart disease.[13]
Carrying out systematic review studies and determining the
effectiveness of cardiovascular interventions plays an important
role in informing about reimbursement decisions, health care
pricing, providing clinical guidance on the use of existing clinical
technologies, interventions strategic purchasing, targeted health
care provision, and the production of scientiﬁc evidence for
policy decisions and ultimately, the optimal allocation of
ﬁnancial resources for health in the ﬁeld of cardiovascular
disease.[14–16]2This study is performed with the following question in mind:
Which treatment interventions are more effective in treating
patients with ischemic cardiomyopathy?
The objectives of this study are:
Primary objective:- Effectiveness of revascularization interventions compared with
medical therapy in patients with ischemic cardiomyopathy
Secondary objectives:
- Determining the effectiveness of treatment by using revascular-
ization interventions in patients with ischemic cardiomyopathy
Determining the effectiveness of treatment by using drug-
therapy in patients with ischemic cardiomyopathy
2. Methods and analysis
2.1. Eligibility criteria
2.1.1. Study characteristics. This systematic review includes
observational (case report, case series, cross-sectional, case–
control, cohort, etc) and interventional (quasi-experimental
studies, randomized controlled trials, community trials, ﬁeld
trials, etc) studies in English and Persian language and examines
the effectiveness of revascularization and medical therapy
interventions in patients with ischemic cardiomyopathy. Animal
studies are not considered. The Preferred Reporting Items for
Systematic reviews and Meta-Analyses for Protocols 2015
(PRISMA-P 2015) and SPIRIT guidelines have been used for
preparing and reporting the protocol of this systematic review.[17]
2.1.2. Types of participants. This systematic review targets
studies in patients with heart failure with ejection fraction< 35%
who have angiography, surgery, or medical treatment.
2.1.3. Setting and time frame. In this systematic review, all
theses, reports, and relevant studies during 1980 to 2017 are
considered.
2.1.4. Report characteristics. Only articles that have abstract
in English and studies whose full text is available are chosen. No
limitation is considered for date of acceptance or publication. As
for publication status, we consider only articles that are published
or in press.
2.1.5. Information sources.Our sources of information include
electronic databases, trial registries, and different types of grey
literature. An electronic search is performed through PubMed,
Cochrane library, Scopus, Web of Science, EMBASE, Tufts
Medical Center Cost-Effectiveness Analysis Registry, NHS
Economic Evaluations Database. To identify appropriate key
words, in addition to MESH terms, popular and commonly-used
phrases stated in the related literature is utilized. First, the search
strategy is developed and completed in PubMed, and then the
same strategy is applied to other databases. Other sources are
searched to identify related grey literature. ProQuest is searched
for dissertations. Meeting abstracts are searched through
SCOPUS, web of science, and pertinent websites. Reference lists
of relevant articles and systematic reviews, and tables of contents
of key journals in this ﬁeld are searched as well.
2.2. Search strategy
Our initial search syntax for PubMed will be:1. “effectiveness”[Title/Abstract] OR “efﬁcacy”[Title/Ab-
stract]) OR “evaluation”[Title/Abstract]
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Abstract]) OR “medical treatment”[Title/Abstract]
“thrombolitic”[Title/Abstract] OR“betablocker”[Title/Ab-3.
stract] OR“calcium blocker”[Title/Abstract] OR“antiarrhyt-
mic”[Title/Abstract] OR“nitrates”[Title/Abstract] OR
“diuretic”[Title/Abstract] OR“antiplatelet”[Title/Abstract]
OR“lipid regulating”[Title/Abstract]
“Revascularization”[Title/Abstract] OR “Percutaneous Cor-4.
onary Intervention”[Title/Abstract]) OR “ Coronary Artery
Bypass Graft ”[Title/Abstract]
“Percutaneous Coronary Intervention”[Title/Abstract]5.
OR“PCI”[Title/Abstract] OR “Percutaneous Coronary
Revascularization”[Title/Abstract] OR“angioplasty”[Title/
Abstract] OR“baloon”[Title/Abstract] OR“Cardiovascular
Surgical Procedure”[Title/Abstract] OR“Atherectomy”
[Title/Abstract]
“Coronary Artery Bypass Graft”[Title/Abstract] OR “6.
Coronary Artery Bypass Surgery”[Title/Abstract]) OR
“CABG”[Title/Abstract] OR “surgical procedure”[Title/
Abstract] OR “vascular grafting”[Title/Abstract]
“Ischemic”[Title/Abstract] OR “Ischemia”[Title/Abstract])7.
OR “Myocardial Ischemia ”[Title/Abstract]
“cardiomyopathy”[Title/Abstract]8.
9. 1 AND 2 AND 7 AND 8
10. 1 AND 4 AND 7 AND 8
11. 1 AND 2 AND 5 AND 6 AND 7 AND 8
12. 1 AND 3 AND 5 AND 6 AND 7 AND 82.3. Study records
2.3.1. Selection process. Two authors independently perform
the primary article screening. First they review the title and
abstract of the articles independently and then their selected
articles will be categorized into 2 groups: relevant and irrelevant.
Articles categorized as irrelevant by both reviewers are eliminated
from the study. Then each reviewer reviews the full text of the
remaining articles and makes a list of articles to be included. The
2 lists are then compared and nonconformities will be discussed.
When an agreement is not reached, the whole team will make the
ﬁnal decision.
2.3.2. Data management. Data are extracted from papers and
entered into data sheets independently by 2 reviewers. These 2
sheets and their differences are checked by a third reviewer. Any
potential difference among reviewers is discussed within the team
and if not resolved, the manuscript authors will be contacted.2.4. Data items
From each article, the following information are extracted: article
ID, author, publication year, study design, sample size, and the
aim of the study and number of deaths and admissions.2.5. Data collection
A data extraction form is developed (Appendix 1, http://links.
lww.com/MD/C155), and study data are independently assessed
and extracted by 2 reviewers2.6. Data synthesis
After searching for studies, the quality of all studies is evaluated
by the Jadad score (Appendix 2, http://links.lww.com/MD/
C155), which had given a score between 0 and 5 based on criteria3such as randomization, blindness, and a decrease in the number
of samples during the study. Score ≥3 in terms of acceptable
quality and score< 3 are considered as an exclusion criterion.[18]
To integrate the results of studies with similar results, meta-
analysis is used, for which ComprehensiveMeta-Analysis (CMA)
software is used. Results are provided using relative risk with
a 95% conﬁdence interval for information. P < 0.05 was
statistically signiﬁcant.[19] To test heterogeneity, the I2 test is used
and if there is a heterogeneity or lack of studies, the random
effects method is used. Funnel chart is used as an indicator of
publication bias. To illustrate meta-analysis results, an accumu-
lation chart is used. This chart is the most common type of
diagram in meta-analysis that displays the information of each
individual study and its ﬁnal outcome.[18]3. Discussion
This protocol presents the methodology of a systematic review
for evaluating effectiveness of revascularization interventions
compared with medical therapy in patients with ischemic
cardiomyopathy.
So far most of the studies that have been done are in relation to
comparison of effectiveness of CABG versus PCI, effect of PCI on
Survival, effectiveness of cardiac resynchronization therapy by the
frequency of revascularization procedures in ischemic cardiomyop-
athy patients,[20–22] or have studied one of the effectiveness
indicators in their studies.[23,24] To our knowledge, this systematic
review will be the ﬁrst to evaluate existing research on the
effectiveness of revascularization interventions compared with
medical therapy in patients with ischemic cardiomyopathy. The
reviewwill beneﬁt patients, healthcare providers, and policymakers.References
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